IMMERVISION
23.11.2021 20:38:09 CET | Business Wire | Press release
Immervision, the world’s leading developer of advanced vision systems combining optics, image processing, and sensor fusion technology, today announced its ultra-wide lenses will be integrated into IONODES’ PERCEPT body camera. This collaboration will give businesses and the general public greater peace of mind, by providing physical security workers with a body camera that can effectively capture in real-time any potential security threats or issues in high resolution and never miss a detail through a Panomorph lens with 180° field of view.
“In the physical security industry, the challenge that most companies face with body worn cameras is that the video fails to effectively capture what’s occurring due to narrow field-of-view and poor image resolution,” said Eric Tasso, President at IONODES. “By selecting Immervision technology and their team of experts, we are providing security, industrial and commercial organizations with the highest-quality wearable cameras to improve safety, enhance security, optimize business processes and provide transparency."
IONODES’ body-worn IoT device is the first of a series of products that combines Immervision’s ultra-wide-angle lens, image processing and sensor technology with IONODES 4K camera, and connects to Wi-Fi, Bluetooth and LTE. IONODES’ device integrates seamlessly with a GPS receiver and 9-axis motion sensor, allowing users to closely follow the field of view in real-time, to stabilize the image and provide location tracking to users, whether for security, prevention, monitoring or entertainment applications
“Over the last 20 years, Immervision has focused on cultivating and perfecting its expertise in advanced vision systems, giving devices in industries such as physical security the ability to truly perceive the world around them,” said Pascale Nini, President and CEO at Immervision. “Immervision and IONODES are deeply committed to offering the best vision systems in the market for security and surveillance, and we look forward to continuing to make more innovative strides in developing high-quality wearable camera devices and AI-based vision systems.”
About Immervision
With over 20 years of innovation, Immervision creates solutions to see beyond human vision. To enable a machine to exceed human vision and unlock the full potential of AI, we develop advanced vision systems combining optics, image processing, and sensor fusion technology. Our Deep Seeing Technology enables hardware and software manufacturers to equip smart devices with the best vision possible for any industry including transportation, security, defense, computing, robotics, and more. www.immervision.com
About IONODES
IONODES is focused on pushing the boundaries of video technology, developing the latest in IP video storage, management and display solutions. Its experience in IP video and strong partnerships with industry leaders deliver innovative products designed to enhance people’s lifestyle while ensuring their safety and security.
IONODES designs, develops, and manufactures IP-based video solutions optimized for use in video surveillance. Its products include smart IP video appliances, such as body worn cameras, video encoders, video wall appliances, recording servers and workstations. The company offers its products through distributors, resellers, and representatives worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123006095/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 12:00:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission
KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 12:00:00 CEST | Press release
KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom